Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ). The genes that govern this process, however, have remained elusive. To this end, we combined distinct mouse strains with transcriptomics to directly identify disease-relevant genes. We show that AD model mice (APP-Tg) with DBA/2 genetic backgrounds have significantly lower levels of Aβ accumulation compared with SJL and C57BL/6 mice. We then applied brain transcriptomics to reveal the genes in DBA/2 that suppress Aβ accumulation. To avoid detecting secondarily affected genes by Aβ, we used non-Tg mice in the absence of Aβ pathology and selected candidate genes differently expressed in DBA/2 mice. Additional transcriptome analysis of APP-Tg mice with mixed genetic backgrounds revealed kinesin light chain-1 (Klc1) as an Aβ modifier, indicating a role for intracellular trafficking in Aβ accumulation. Aβ levels correlated with the expression levels of Klc1 splice variant E and the genotype of Klc1 in these APP-Tg mice. In humans, the expression levels of KLC1 variant E in brain and lymphocyte were significantly higher in AD patients compared with unaffected individuals. Finally, functional analysis using neuroblastoma cells showed that overexpression or knockdown of KLC1 variant E increases or decreases the production of Aβ, respectively. The identification of KLC1 variant E suggests that the dysfunction of intracellular trafficking is a causative factor of Aβ pathology. This unique combination of distinct mouse strains and model mice with transcriptomics is expected to be useful for the study of genetic mechanisms of other complex diseases.
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ). The genes that govern this process, however, have remained elusive. To this end, we combined distinct mouse strains with transcriptomics to directly identify disease-relevant genes.
We show that AD model mice (APP-Tg) with DBA/2 genetic backgrounds have significantly lower levels of Aβ accumulation compared with SJL and C57BL/6 mice. We then applied brain transcriptomics to reveal the genes in DBA/2 that suppress Aβ accumulation. To avoid detecting secondarily affected genes by Aβ, we used non-Tg mice in the absence of Aβ pathology and selected candidate genes differently expressed in DBA/2 mice. Additional transcriptome analysis of APP-Tg mice with mixed genetic backgrounds revealed kinesin light chain-1 (Klc1) as an Aβ modifier, indicating a role for intracellular trafficking in Aβ accumulation. Aβ levels correlated with the expression levels of Klc1 splice variant E and the genotype of Klc1 in these APP-Tg mice. In humans, the expression levels of KLC1 variant E in brain and lymphocyte were significantly higher in AD patients compared with unaffected individuals. Finally, functional analysis using neuroblastoma cells showed that overexpression or knockdown of KLC1 variant E increases or decreases the production of Aβ, respectively. The identification of KLC1 variant E suggests that the dysfunction of intracellular trafficking is a causative factor of Aβ pathology. This unique combination of distinct mouse strains and model mice with transcriptomics is expected to be useful for the study of genetic mechanisms of other complex diseases.
mouse-to-human translation | alternative splicing A lzheimer's disease (AD) is a common cause of dementia that is characterized by the accumulation of amyloid-β (Aβ) peptide. Its causes (especially of sporadic AD, which comprises the majority of AD cases), however, are still largely unknown, and no efficient treatment exists. Since the first AD risk gene, apolioprotein E (APOE), was identified, over 1,300 genetic studies have been done (www.alzgene.org) (1) , and ∼10,000 human genomic samples have identified AD risk genes (2) (3) (4) (5) (6) (7) (8) . Regardless, these genes cannot account for the estimated 60-80% hereditary risk of AD (9) . Also, they do not reveal their role in the cause of AD (10) , because complex diseases, including AD, are often explained by the heterogeneity of diseases, uncontrollable environmental factors, and the complexity of human genome variation, which complicate conclusions from genome studies (11) (12) (13) .
These limitations can be resolved by using mice. Mice with a mixed genetic background prepared from inbred mouse strains have simple genetic backgrounds, which drastically increase the statistical power for the identification of disease-related genes (14) . AD is a complex disease not only genetically but also, neuropathologically and symptomatically (11) , with its clinical diagnosis often ambiguous. Although increased Aβ levels in the brain are central to the pathology of AD, Aβ levels are difficult to measure in humans. In contrast, Aβ levels can be directly measured in mice. Furthermore, in human studies, although aging is the strongest risk
Significance
Genetic studies of common complex human diseases, including Alzheimer's disease (AD), are extremely resource-intensive and have struggled to identify genes that are causal in disease. Combined with the costs of studies and the inability to identify the missing heritability, particularly in AD, alternate strategies warrant consideration. We devised a unique strategy that combines distinct mouse strains that vary naturally in amyloid-β production with transcriptomics to identify kinesin light chain-1 (Klc1) splice variant E as a modifier of amyloid-β accumulation, a causative factor of AD. In AD patients, the expression levels of KLC1 variant E in brain were significantly higher compared with levels in unaffected individuals. The identification of KLC1 variant E suggests that dysfunction of intracellular trafficking is causative in AD.
factor for AD, it is not practical to collect same age samples or control for environmental factors. Mice, however, can be aged in equally controlled environments and analyzed at exactly the same age. Despite these significant advantages, most of the rodent genomic studies addressing human diseases, including AD, have not identified targets at the molecular level (15, 16) . Thus, we applied transcriptomics: a straightforward approach to identify genes compared with conventional genome studies based on linkage disequilibrium between markers (17).
We first generated mice with different genetic backgrounds that accumulated varying amounts of Aβ. Then, instead of using standard genetic approaches, we performed genome-wide transcriptome analysis on the mice. We identified a specific splice form of kinesin light chain-1 (Klc1), variant E, as a modifier of the Aβ accumulation. Notably, the transcript levels of KLC1 variant E were significantly higher in pathologically diagnosed AD patients with confirmed levels of excessive Aβ compared with controls. A functional role for KLC1 variant E was shown by manipulating its expression levels in neuroblastoma cells and showing that this variant can modulate Aβ production. This study shows that the central pathology of AD is modified by the splicing of KLC1 and suggests that the combination of animal models and transcriptomics is an efficient approach to identifying key genes in common complex diseases.
Results DBA/2 Genetic Backgrounds Suppress Aβ Levels in AD Model Mice. To examine the impact on Aβ accumulation by genetic background, we prepared amyloid precursor protein (APP)-Tg mice with mixed genetic backgrounds by crossing the Tg2576 mice with the phenotypically distinct strains C57BL/6 (B6), SJL, and DBA/2 (DBA). We obtained six groups of APP-Tg mice, and each group contained different mixture ratios of the three strains in their genetic background (Fig. 1A) . We analyzed these APP-Tg mice at 12 mo of age to assess the effects on Aβ accumulation by genetic background (n = 59). The levels of Aβ40 and Aβ42 in a 1% Triton-X ( Fig. 1 B-D) and 6 M guanidine HCl (GuHCl) (Fig. 1 E-G) fraction from brain were measured by ELISA. The levels of Aβ ranged more than 10-fold, and the mice carrying DBA alleles (dark blue and light blue) had lower amounts of Aβ Compared with Aβ40 levels in no DBA mice, Aβ40 levels in one-half DBA and high DBA mice were −48.4% (P = 0.017) and −73.1% (P < 0.0001) lower, respectively. (G) The levels of GuHCl Aβ42 in high DBA mice were −57.7% (P = 0.0002) and −50.8% (P = 0.011) lower compared with Aβ42 levels in no DBA and one-half DBA mice, respectively. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 [TukeyKramer Honestly Significant Difference (HSD)]. Error bars indicate SEM. Aβ levels are shown in log10 scale (picograms Aβ per milligram total protein).
( Fig. 1 B and E) . Compared with mice with no DBA alleles, the mice carrying 75% DBA alleles had lower levels of both forms of Aβ in these fractions (−74.7 to −57.7%, P ≤ 0.0001-0.0002) ( Fig.  1 C, D , F, and G). Notably, the expression levels of APP were not affected by the genetic backgrounds (Fig. S1 ). These findings drove us to search for the gene(s) in DBA mice that suppresses Aβ accumulation.
Mouse Transcriptomics Identify Klc1 as a Modifier of Aβ Accumulation.
Most previous mouse genomics studies (14, 15) , including ones performed on AD (18, 19) , failed to identify modifiers at the molecular level. Thus, instead of genomics, we applied transcriptomics, which is a more straightforward approach for identifying candidate molecules (17) . We used 12 arrays for inbred mice (non-Tg) analyses and 28 arrays for the APP-Tg mice of mixed genetic backgrounds ( Fig. 2A) We applied strict criteria in this selection: the fold change had to be equal to or more than 1.5, and the false discovery rate was set to 0.001. In total, 54 probes were identified, with the signals of 47 probes being lower and the signals of 7 probes being higher in DBA mice than the signals in either B6 or SJL (Table S1 ).
In the final step, we examined the correlation between the expression levels of these 54 probes and Aβ40 levels in the GuHCl fraction in APP-Tg mice. Using strict selection criteria (Pearson product moment correlation false discovery rate = 0.001), we identified a total of four probes that correlated with Aβ levels. Notably, the two probes (probe IDs 4050133 and 6130468) that positively correlated with Aβ accumulation both detected the same transcript: Klc1 (also known as Kns2) (Fig. 2B) .
In addition to these two Klc1 probes, the arrays have another three Klc1 probes (Fig. S2) (probe IDs 540139, 4060520, and 7330358) that, although they did not pass our strict genome-wide screen, provide data still worth considering. Two probes (540139 and 4060520) showed lower signal levels in DBA compared with other inbred strains (P < 0.0001 before multiple testing correction) and correlated with levels of Aβ accumulation in APP-Tg mice (P < 0.0001 before multiple testing correction). Similar to the probes identified above, these probes detect exons with complex splicing patterns. By contrast, probe 7330358 was not affected by the mouse strain (P = 0.91 between DBA and B6, P = 0.30 between DBA and SJL) and did not correlate with Aβ levels (P = 0.49). This probe exists in a region common to all splice variants of Klc1. Thus, all four probes with signals that were suppressed by the DBA genetic background and correlated with Aβ levels are located in the splice region of Klc1. These findings indicate that a splice variant of Klc1 might be involved in the mechanism of Aβ accumulation.
Levels of a Specific Splice Variant but Not Total Klc1
Are Different in the DBA Strain. Because the array probes cannot distinguish the multitude of splice variants of Klc1, we developed variant-specific real-time quantitative PCR (QPCR) assays to identify which splice variant of Klc1 modulates Aβ accumulation. We measured the mRNA expression levels of Klc1 variants A-E in mouse hippocampus in addition to the total levels of Klc1 expression by detecting the common region (exons 3 and 4) of all splice variants (Klc1 All). To examine whether the expression levels of each Klc1 variant were affected by the DBA genetic background independent of Aβ accumulation, we measured expression levels in inbred mice (non-Tg mice) at 6 (n = 11) and 12 mo of age (n = 20) (Fig. 3A) . Consistent with the array results (probe ID 733035), there was no observed difference in the Klc1 All expression levels among the three strains (DBA, SJL, and B6) at 6 (ANOVA: P = 0.95) or 12 mo of age (ANOVA: P = 0.51) (Fig. 3A , Left). In contrast to Klc1 All, the expression levels of Klc1 variant E were significantly lower in DBA mice than expression levels in SJL and B6 mice at both ages (Fig. 3A , Right). However, the Klc1 splice variants A-D did not show consistent differences between DBA and the other two strains (Fig. S3 ).
Klc1 Variant E but Not Total Klc1 Correlates with the Levels of Aβ Accumulation. To examine whether Klc1 variant E affects Aβ accumulation in vivo, we measured the expression levels of Klc1 variant E in APP-Tg mice with mixed genetic backgrounds (n = 59). The levels of Klc1 variant E were significantly correlated with the levels of all forms of Aβ [Aβ40 (Pearson product moment correlation R 2 = 0.39, P < 0.0001; significant threshold with Bonferroni correction = 0.002) and Aβ42 (R 2 = 0.24, P < 0.0001) in the Triton fraction; Aβ40 (R 2 = 0.33, P < 0.0001) and Aβ42 (R 2 = 0.21, P = 0.0002) in the GuHCl fraction] (Fig. 3B , Right). In contrast, the expression levels of Klc1 All and the other variants did not correlate with the levels of Aβ (except variant A but only with Aβ40 in Triton-X fractions) (Fig. 3B , Left and Fig. S4 ). The correlation between Klc1 variant E and Aβ was unlikely caused by Aβ accumulation for many reasons, including no elevation of the levels of Klc1 variant E in APP-Tg mice that had abundant Aβ compared with those Aβ in non-Tg littermates that had no Aβ pathology (Fig. S5 ). In addition to the array data ( Fig. S2 ), these QPCR data ( Candidate probes were narrowed down by three steps. In the first step, 13,309 probe with signals that were reliably detectable in all arrays were selected. In the second step, 47 probes with expression levels that were significantly lower in DBA inbred mice and seven probes with expression levels that were significantly higher in DBA compared with the other strains were selected for additional analysis [fold change ≥ 1.5; false discovery rate (FDR) = 0.001] (Table S1 ). In the third step, two probes with expression levels that were significantly and positively correlated with Aβ levels and two probes with expression levels that were significantly and negatively correlated with Aβ were ultimately identified (FDR = 0.001). (B) Probes identified by genome-wide transcriptomics for Aβ modifier genes. All array data are deposited in the Gene Expression Omnibus (accession no. GSE40330).
Klc1 Allele in DBA Mice Decreases the Levels of Klc1 Variant E and Aβ Accumulation in APP-Tg Mice with Mixed Genetic Backgrounds. Because the genetic component of mRNA expression variation is often caused by differences produced by cis-acting polymorphisms (20), we genotyped the Klc1 region of APP-Tg mice with mixed genetic backgrounds (Fig. 3B) Although failing to identify any AD-related genes, two groups reported differences in Aβ levels among mouse strains (18, 19, 21) . Collectively, these data suggest that B6 and SJL are high Aβ mouse strains and that A/J and DBA are low Aβ mouse strains (Fig. S6A,  Left) . We obtained SNP data from the mouse phenome database (www.jax.org/phenome) (22) to examine whether genomic variance in Klc1 affects Aβ accumulation in these mouse strains. Remarkably, all SNP variation in Klc1 distinguishes the two types of strains (high and low) (Fig. S6A) , despite the fact that strains of a type are not the closest relatives to each other ( Fig. S6B) (23) .
KLC1 Variant E Affects Aβ Production in Neuroblastoma Cells. To test the direct effect on amyloid pathology by KLC1 variant E, we manipulated the expression levels of KLC1 variant E in neuroblastoma cells, collected the culture media, and assessed Aβ40 and Aβ42 production by ELISA. The overexpression of Klc1 variant E into N2a cells increased both Aβ40 (+18.4 ± 3.4%, P = 0.0009) and Aβ42 (+9.27 ± 2.7%, P = 0.024) secretion (Fig. 4A) . Next, we knocked down total levels of KLC1 (KLC1 All siRNA), which includes KLC1 variant E or KLC1 variant E alone (KLC1 E siRNA) in SH-SY5Y cells (Fig. 4 B and C) . The suppression of KLC1 or KLC1 variant E alone reduced both Aβ40 (−44.7 ± 2.6%, P < 0.0001 by KLC1 E siRNA) and Aβ42 secretion (−39.3 ± 0.6%, P < 0.0001 by KLC1 E siRNA) (Fig. 4C) . These findings strengthen the causative role of KLC1 variant E in AD and suggest that aberrant splicing of KLC1 impacts the accumulation of Aβ at the stage of its production.
Expression Levels of KLC1 Variant E Are Higher in AD. Human and mouse KLC1 splice variants share extensive similarities in not only amino acid sequence but also, exon composition (24) (Fig. S7) , implying that each splice variant has an important function and is likely conserved between mouse and human. Thus, we measured the expression levels of KLC1 variant E and KLC1 All in the hippocampus of autopsy-confirmed AD (n = 10) and control patients (n = 14) (Table S2 ). Although those of KLC1 All were not different between the two groups (P = 0.18) (Fig. 5A) , the expression levels of KLC1 variant E were significantly higher in AD (+30.7%, P = 0.0096 Student t test) compared with control subjects (Fig. 5B) .
Gene expression profiles in peripheral blood and brain are reported to share similarities (20) , thus we measured the levels of KLC1 All and variant E by QPCR in peripheral lymphocyte from control (n = 17) and AD (n = 47) subjects (Table S3) . Although the levels of KLC1 All were not significantly different between the two (P = 0.56) (Fig. 5C ), the expression levels of KLC1 variant E were significantly higher in AD (+25.0%, P = 0.0013, Student t test) compared with control subjects (Fig. 5D ). Because Aβ is not believed to accumulate in lymphocytes, the elevation of KLC1 variant E expression levels was unlikely to be the result of Aβ deposition. Taken together, these data show that the levels of KLC1 splice variant E but not total KLC1 impact AD pathology in both humans and APP-Tg mice.
Discussion
By combining distinct mouse strains and model mice with transcriptome analysis, we identified a causative molecule in AD (Klc1 splice variant E), finding that it accumulates with different levels of Aβ that are based on the different mouse genetic backgrounds. Fig. 3 . Klc1 splice variant E and the levels of Aβ. (A) Expression levels of Klc1 variant E and Klc1 All in three mouse strains (non-Tg mice). mRNA expression levels of (Left) Klc1 All and (Right) Klc1 E in each mouse strain at (Upper) 6 (n = 4 DBA, 4 SJL, and 3 B6) and (Lower) 12 mo of age (n = 7 DBA, 6 SJL, and 7 B6) were measured by QPCR. The expression levels in DBA were normalized to 100. Error bars indicate SEM. P values were calculated by the TukeyKramer HSD test and considered significant when they were less than 0.004 (0.05/12 tests) according to Bonferroni correction for multiple testing. **P < 0.01; ***P < 0.001; ****P < 0.0001. (B) Relationship between the levels of Aβ accumulation and Klc1 expression and number of DBA alleles of Klc1 in APPTg mice with mixed genetic backgrounds. Expression levels of (Left) Klc1 All and (Right) Klc1 E in APP-Tg mice with mixed genetic backgrounds (n = 59) are shown on the x axis. Aβ40 and Aβ42 levels in Triton-X fraction (TX) and Aβ40 and Aβ42 levels in the GuHCl fraction in mouse brain are shown in log10 scale on the y axis (picograms Aβ per milligram total protein). Lines show the correlation between the levels of Klc1 and Aβ. P values are considered significant when they are less than 0.002 (0.05/24 tests) according to Bonferroni correction for multiple testing. The color of dots indicates the genotype of Klc1: blue, mice carrying two Klc1 alleles from DBA strain; gray, one Klc1 allele from DBA; and red, no Klc1 allele from DBA. The mean expression levels in mice carrying two DBA alleles were normalized to 100.
This finding is supported by multiple approaches, including mouse transcriptomics, mouse genome, human brain transcript, and human lymphocyte transcript analyses, along with functional analysis of KLC1 variant E in neuroblastoma cells. Model mice with simple genetic backgrounds offer important advantages, such as controlled environmental factors and high detection power, which are amplified combined with transcriptional analysis. Complex diseases, including AD, show a continuum of clinical phenotypes, such as the levels of Aβ accumulation. Transcriptome analysis, therefore, is preferred, because it is highly concordant with the disease state and expected to provide an accurate molecular view of a complex disease (25) . Additionally, although quantitative trait loci analysis and a genome-wide association study identify genetic markers, they do not point to specific genes, whereas transcriptomics does (17) . In fact, thus far, less than 1% of rodent quantitative trait loci studies have identified molecular targets (14, 15) . Finally, although the function of most genetic variation is unknown (10), gene expression variation offers clear functional targets.
The combination of transcriptional analysis and mice also minimizes the drawbacks found in human transcriptomic studies, because studies on AD examining brain tissue have produced largely discordant results (26) . Human transcriptomic data suffer from serious noise because of tissue quality and variation in the agonal state of the patients. These problems can be circumvented in mice by isolating high-quality RNA from animals reared and then killed in highly controlled conditions. Additionally, transcriptomics studies comparing disease and control conditions identify not only causative genes but also, secondarily affected genes. To focus on causative genes, we determined the strain effects on gene expression profiles before the Aβ analysis in APP-Tg mice. Using non-Tg mice in the absence of Aβ pathology enabled us to select the genes with expression levels that were changed by the genetic background but not the Aβ pathology (Fig. 3A, second selection step) . Finally, using Tg mice with mixed genetic backgrounds, we confirmed that Aβ levels were negatively dependent on the number of DBA alleles in the Klc1 regions (Fig. 3B, Right) . DNA sequence variation as causative in disease has also been implicated in other studies (27) (28) (29) . In summary, the strengths of each approach (model mice with mixed genetic backgrounds and transcriptomics) are synergized, whereas their respective drawbacks are minimized.
Kinesin-1 is a plus end-directed motor comprised of two kinesin heavy chains and two KLCs that associate in a 1:1 stoichiometry (30). KLC1, with expression that is enriched in neuronal tissue (31) , is required for cargo binding and the regulation of motility. Among myosin and kinesin family members, splicing is a common strategy to facilitate motor cargo selection, and the many splice variants of KLC1 in the C-terminal region likely allow it to select different cargos (32) . Notably, all KLC1 splice variants discovered thus far share extensive similarity between human, mouse, and rat (Fig. S7 ) (24) , suggesting an essential role for each variant. The importance of splicing of KLC1, however, has been relatively ignored; in most KLC1 studies, all variants of KLC1 have been abolished, or the single major isoform has been overexpressed. In a mouse model that knocks out one allele of the Klc1 gene, an increase in Aβ was seen (33) , whereas knocking down KLC1 in stem cells decreased Aβ (34) . These seemingly conflicting results could be explained by splicing of KLC1. The transport of APP requires KLC1 to act as a direct or indirect motor cargo adaptor (35) (36) (37) (38) (39) (40) , and changes in the splicing of KLC1 may alter such interactions. Additional studies are required to fully understand the mechanistic role of KLC1 in AD.
Disruption of trafficking is usually thought to be a result of Aβ pathology. However, the present study and several other studies (33-36, 38, 39, 41) show just the opposite, where alterations in trafficking can modify Aβ pathology. Moreover, recent genome-wide association studies identified trafficking-related genes (PICALM, BIN1, CD33, and CD2AP) as AD risk genes (42) , further suggesting that trafficking is a causative factor of AD.
In conclusion, Klc1 variant E was identified as an Aβ modifier using a hypothesis-free transcriptomics approach. Notably, common interstrain genetic variations (polymorphisms) affected the expression levels of Klc1 variant E and modified Aβ accumulation in mice. Subsequently, a corresponding variation in the expression levels of KLC1 variant E in sporadic AD in the human population was discovered. These findings, along with other studies (33) (34) (35) (36) (37) (38) (39) 41) , add a critical element to the understanding of AD etiology and implicate intracellular trafficking as a causative factor in Aβ accumulation. The present study also shows that the combination of animal models and transcriptomics is an effective strategy for identifying unique genes causative in complex human diseases.
Materials and Methods
Animals. We crossed Tg2576 mice with a genetic background of 50% B6 and 50% SJL onto three inbred strains (B6, SJL, and DBA) for one to three (B and C) The relative levels of total mRNA levels of KLC1 and KLC1 variant E and the protein levels of Aβ40 and Aβ42 in the culture medium after 72 h of SH-SY5Y knocked down by (B) KLC1 All siRNA or KLC1 All control siRNA or (C) KLC1 E siRNA or KLC1 E control siRNA (n = 4 per group). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (Student t test without multiple testing correction). Error bars indicate SEM. . Levels of total KLC1 and KLC1 variant E in humans. Brain expression levels of (A) KLC1 All and (B) KLC1 E were measured in control (n = 14) and AD (n = 10) patients by QPCR. Lymphocyte expression levels of (C) KLC1 All and (D) KLC1 E were also measured in control (n = 17) and AD (n = 47) patients. Long and short green bars indicate mean and SE, respectively. The mean expression levels of the control were normalized to 100.
generations and intercrossed the offspring. As a result, six groups of APP-Tg mice with different percentages of background genomes from B6, SJL, and DBA were generated (Fig. 1A) . In the first APP-Tg mouse group (n = 16), 62.5% of the genome randomly came from B6, and 37.5% of the genome randomly came from SJL, which was expected. In the second group (n = 14), mice had a mixture of 84% SJL and 16% B6. In the third group (n = 10), mice had 69% SJL and 31% B6. In the fourth group (n = 8), mice had 50% DBA, 31% B6, and 19% SJL. In the fifth group (n = 3), mice had 50% DBA, 42% SJL, and 8% B6. In the sixth group (n = 8), mice had 75% DBA, 16% B6, and 9% SJL.
To minimize variance in the animal samples, all animals were killed at 10:00 AM at the age of 12 (or 6) mo, and they were killed within 1 wk of each another. Animals were perfused before brain dissection with 15-20 mL 0.05 M tris-buffered saline (pH 7.2-7.4) containing a Protease Inhibitor Mixture (P2714; Sigma). The hippocampus, frontal region, residual cortex, and cerebellum were dissected out and snap-frozen in liquid nitrogen (43) . All animal procedures were performed according to the protocols approved by the Osaka University Animal Care and Use Committee.
Human Brain. Brains were obtained from the brain bank of the Choju Medical Institute of Fukushimura Hospital. We examined the hippocampi of 27 patients. Three poor-quality samples with RNA integrity numbers, determined by the 2100 Bioanalyzer (Agilent), that were under seven were excluded from the analysis. All brains, including brains excluded from the analysis, received a pathological diagnosis (AD: n = 10, control: n = 14) (Table S2 ). AD diagnosis was according to the criteria of the Consortium to Establish a Registry for Alzheimer's Disease and Braak Stage. Control patients had died without dementia. The protocol used was approved independently by the local ethics committees of Osaka University and Fukushimura Hospital.
Human Blood Samples. The AD cases were recruited from Osaka University Hospital (44, 45) and met the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria for probable AD. The control cases were recruited from healthy elderly volunteers with no history of dementia or other neuropsychiatric diseases (44, 45) . The purpose and significance of the present study were explained in detail to each patient and his/ her family, and all subjects provided their informed consent. The protocol for specimen collection was approved by the genome ethical committee of Osaka University Graduate School of Medicine. DNA was extracted from white blood nuclear cells using the QIAmp DNA Blood Maxi Kit (QIAGEN). RNA was extracted using a Paxgene tube (QIAGEN) following the manufacturer's protocol.
Additional information regarding Aβ measurements, Western blotting, expression arrays, QPCR, genotyping, cell cultures, reanalysis of two other studies using a mouse phenome database, and statistical analysis is in SI Materials and Methods. 
SI Materials and Methods
Amyloid-β Measurements in Mouse Brain. Amyloid-β (Aβ) measurements were performed in the remaining cortical samples as previously described (1) . Using a BioPulverizer (BioSpec Product), samples were powdered and divided into two tubes. Because our preliminary experiments showed that the largest contributor to technical variance was at the homogenization step, we performed two independent homogenizations of powdered tissue at different times and measured Aβ levels in the two independently homogenized samples.
Brain samples were homogenized with five wet weight volumes of 1% Triton-X and 25 mM tris-buffered saline (TBS) (pH 7.9) with Complete Protease Inhibitor Mixture (Roche). After sitting on ice for 3 h, the homogenized samples were centrifuged at 100,000 × g for 20 min at 4°C. The supernatants were used for Aβ ELISAs. The pellets were mixed with five wet weight volumes of 5 M guanidine HCl and sonicated at room temperature. After rotation for 2 h at room temperature, the mixtures were diluted with TBS and centrifuged at 4,000 × g for 20 min at 4°C. The supernatants were neutralized before loading onto the ELISAs plates. Aβ levels were measured by ELISA following the manufacturer's protocol (Wako).
APP Western Blotting. Powdered brain samples were homogenized with 10 wet weight volumes of 1% Nonidet P-40, 10 mM Tris·HCl (pH 7.8), 150 mM NaCl, and 1 mM EDTA lysis buffer. Western blotting was performed using 22C11 antibody (NAB384; Chemicon).
Expression Array. The quality of RNA was assessed for each sample using an Agilent 2100 Bioanalyzer (Agilent Technologies). Forty RNA samples were analyzed by the Illumina Mouse Ref-8 Expression BeadChip (Illumina) using standard protocols. All expression profiles were extracted and rank invariant-normalized using BeadStudio software (Illumina). The levels of Aβ were transformed into log form and analyzed further using GeneSpring GX, version 10 (Agilent Technology) and JMP 9 (SAS Institute).
Quantitative PCR Primers and Probes. The ABI predesigned quantitative PCR (QPCR) assay (Mm00492936_m1) with primers located in exons 3 and 4 was used to detect all splice forms of kinesin light chain-1 (Klc1). Using Primer Express (Applied Biosystems), splice form-specific QPCR assays were designed as described previously (2) . Each reverse primer was designed on the exon boundaries specific to each splice form. Absence of SNPs in these primers was verified by Ensemble (www.ensembl.org). The specific amplification of these primers was confirmed as follows: first, in silico analysis using Primer-Blast (www.ncbi.nlm.nih.gov/tools/ primer-blast/index.cgi?LINK_LOC=BlastHome); second, assessment of the dissociation curve of the amplicons; also, in some cases, gel electrophoresis of the amplicons and/or the absence of amplification with mismatched splice forms. The forward primer common for Klc1 variants A-E specific assays was GTCTCAATATGGACGTGGTCAAGTA, and the TaqMan MGB probe common for each splice specific assay was TCCGTCAGGGCCACT. The reverse primers were Klc1A: GGGCGGCTAGGCTTCCT; Klc1B: CCCGAGCTTCATC-TTTCTCATTT; Klc1C: CATCCCATTCCACTCTACGC; Klc1D: GCCATCCCCATTCCACTCTA; and Klc1E: GATCCAGTGC-CATCTTCCTCC. QPCR assays for all splice forms of KLC1 and specific assays for each splice forms were also designed. The forward primer common for each KLC1 assay was TCTCGTAAA-CAGGGTCTTGACAATG. The TaqMan MGB probe common for each Klc1 assay was ATGACCCTGAGAACAT. The reverse primer detecting all splice forms of KLC1 was GGCCACTCT-CGTACTTGACCAC, and the reverse primer for KLC1E was TGCCATCTTCCTCCCCTCC. For endogenous control assays, we used TaqMan Gene Expression Assays (Endogenous Control). The assay identifications were Hs99999905_m1 for GAPDH, HPRT1 Hs99999909_m1 for HPRT1, Hs99999901_s1 for human and mouse 18S, and Mm00446968_m1 for Hprt1.
Genotyping. Genotyping of Klc1 (rs6390948, rs13481650, rs13481653, and rs13481656) and APOE polymorphisms was performed by the TaqMan SNP assay and ABI Prism 7900HT sequence detection system (Applied Biosystems) as previously described (3, 4) .
Cell Culture. pFLC1 Vector-Mouse Klc1-D cDNA was purchased from DNAFORM. mKlc1-D cDNA encoding 615 aa (GenBank accession no. NM1025360.2) was subcloned into a pcDNA3.1(-) vector (Invitrogen) at the EcoR1/BamH1 sites to produce pcDNA3.1 (-)-mKlc1-D. pcDNA3.1(-)-mKlc1 D had 27 bases deleted from 1819 to 1845 using the QuikChange site-directed mutagenesis kit (Stratagene) to produce pcDNA3.1(-)-mKlc1-E. The primers for mutagenesis were TGACGGAGGGGAGGAAGATGGCACTG-GATCTT (sense) and AAGATCCAGTGCCATCTTCCTCCCC-TCCGTCA (antisense). The expression of Klc1 variant E was confirmed by Western blotting using antibody UT109 (1:500) (5).
A neuronal cell line (mouse neuroblastoma Neuro2A cells) was cultured in DMEM with 10% (vol/vol) FCS. One day before transfection, cells were plated at 1.5 × 10 4 cells/cm 2 onto six-well plates coated with 0.01% poly-L-lysine (Wako). N2a cells were transfected with Klc1 variant E or empty plasmid using HilyMax (Dojindo) according to the manufacturer's protocol (n = 11 per group). The medium was changed after 6 h; 72 h after transfection, medium was collected and centrifuged at 70 × g for 1 min. Aβ levels in the supernatant was measured by ELISA [Human/ RatβAmyloid(40) ELISA Kit, Catalog 294-62501 and Human/Rat βAmyloid(42) ELISA Kit, Catalog 290-62601; Wako].
Using BLOCK-iT RNAi Designer (Invitrogen), we developed KLC1 variant E Stealth siRNA (KLC1 E siRNA), which was designed for the exon boundary specific to KLC1 splice variant E, KLC1 ALL Stealth siRNA (KLC1 All siRNA), which was designed for the common exon for all splice variants, and custom scrambled Stealth siRNAs for KLC1 E or KLC1 All. The siRNA sequences were KLC1 E siRNA: GAGGAAGAUGGCACUG-GAUCUUUAA; KLC1 E control: GAGGAUAGGACUCGG-UAUCUAGUAA; KLC1 All siRNA: UCCGGAUCAUGUU-UGAUUUCUCCUC; and KLC1 All control: GAGAAAGAA-CUUACACUAGCAGGGA.
Neuronal cell line stably expressing APPsw (human neuroblastoma SH-SY5Y) was cultured in DMEM/F12 (1:1; Gibco) with 5% FCS. One day before transfection, cells were plated at 2.0 × 10 5 cells/dish onto 6-cm plates; 2.7 (KLC1 E siRNA and KLC1 E control) or 27 pmol siRNA (KLC1 ALL siRNA and KLC1 ALL control) were mixed with 10 μL Lipofectamine RNAiMAX (Invitrogen) in 1 mL Opti-MEM Reduced Serum Medium (Gibco). The mixture was added to the cells in 5 mL culture medium without antibiotics; 72 h after transfection, medium was collected, and RNA was isolated (RNeasy Mini Kit; Qiagen). Aβ levels in the medium were measured by ELISA. The levels of mRNA were measured by QPCR as described above.
Reanalysis of Two Other APP-Tg Mice Studies and a Mouse Phenome
Database. Two groups have reported genomic regions that may control Aβ accumulation in mice (6-8). The genomic regions, however, did not coincide, and the reports did not identify the region containing Klc1. In contrast to the discordant results of the gene screening, the phenotype of Aβ accumulation in each mouse strain was consistent between those reports and the present one (Fig. S4) . To reexamine the association between the Klc1 allele and Aβ accumulation using the results from these two studies and our data, we searched the mouse phenome database (www.jax.org/phenome) (9) and obtained SNPs data. In the mouse phenome database, the CGD1 dataset was selected and thresholded for confidence levels on imputed calls set at 0.9 (default).
Genomic region chromosome 12 (11.995674-113 .039450 Mbp; Build 37) was selected as the Klc1 region. The search was performed on August 22, 2011.
Statistical Analysis. The statistics for array expression analysis are described above and in Results, Mouse Transcriptomics Identify Klc1 as a Modifier of Aβ Accumulation. Other statistical analyses were performed using JMP 9 (SAS Institute). Unless otherwise specified, a two-sided P value less than 0.05 was considered significant. Lines show the correlation between the levels of Klc1 and Aβ. P values are considered significant when they are less than 0.002 (0.05/24 tests) according to Bonferroni correction for multiple testing. Blue, mice carrying two Klc1 alleles from DBA strain; gray, mice carrying one Klc1 allele from DBA; red, mice carrying no Klc1 allele from DBA. Mean expression levels in mice carrying two DBA alleles were normalized to 100. 
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Fig. S5. Brain expression levels of Klc1 splice variants and total Klc1 in non-Tg and APP-Tg mice. Expression levels of (A-E) Klc1 splice variants and (F) total Klc1 in non-Tg (n = 9) and APP-Tg mice (n = 4) littermates at 12 mo of age were measured by QPCR. (E) The mRNA levels of Klc1 variant E were not elevated in APPTg mice (−7.44%, P = 0.52; Student t test) compared with those levels in non-Tg littermates. The expression levels of (A-D) the other splice variants of Klc1 and (F) total levels of Klc1 (Klc1 All) were also similar between APP-Tg and non-Tg mice. These data show that Aβ did not affect the overall expression levels of Klc1 in any form, strengthening the evidence that the correlation between Klc1 variant E and Aβ in APP-Tg mice ( 
